Telmisartan improves morphologic and functional changes in both left ventricular myocardium and carotid arterial wall in patients with hypertension: Assessment by tissue doppler imaging and carotid ultrasonography

Echocardiography

Volumn 27, Issue 7, 2010, Pages 864-872

  Mizuguchi, Yukio ^a   Oishi, Yoshifumi ^a   Miyoshi, Hirokazu ^a   Iuchi, Arata ^a   Nagase, Norio ^a   Oki, Takashi ^a  

^a National Hospital Organization   (Japan)

Author keywords

arterio and cardioprotective effects; carotid ultrasonography; hypertension; telmisartan; tissue Doppler imaging

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TELMISARTAN; TRIACYLGLYCEROL; URIC ACID;

ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; HEART LEFT VENTRICLE; HEART MUSCLE; HEART RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MALE; MORPHOLOGY; MULTIVARIATE ANALYSIS; NORMAL VALUE; PRIORITY JOURNAL; PULSE PRESSURE; REGRESSION ANALYSIS; RELAXATION TIME; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING; TREATMENT DURATION; VELOCITY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; CAROTID ARTERIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77955821722     PISSN: 07422822     EISSN: 15408175     Source Type: Journal    
DOI: 10.1111/j.1540-8175.2010.01163.x     Document Type: Article

References (47)

1. Vasan RS, Larson MG, Benjamin EJ, et al : Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999 33 : 1948 1955.
2. Hogg K, Swedberg K, McMurray J : Heart failure with preserved left ventricular systolic function. Epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004 43 : 317 327. (Pubitemid 38167688)
3. Yancy CW, Lopatin M, Stevenson LW, et al : Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol 2006 47 : 76 84.
4. Fischer M, Baessler A, Hense HW, et al : Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 2003 24 : 320 328.
5. Fonarow GC, Stough WG, Abraham WT, et al : Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007 50 : 768 777.
6. Inouye I, Massie B, Loge D, et al : Abnormal left ventricular filling: An early finding in mild to moderate systemic hypertension. Am J Cardiol 1984 53 : 120 126.
7. Zabalgoitia M, Rahman SN, Haley WE, et al : Comparison in systemic hypertension of left ventricular mass and geometry with systolic and diastolic function in patients < 65 to > or = 65 years of age. Am J Cardiol 1998 82 : 604 608.
8. Saba PS, Ganau A, Devereux RB, et al : Impact of arterial elastance as a measure of vascular load on left ventricular geometry in hypertension. J Hypertens 1999 17 : 1007 1015.
9. Kawaguchi M, Hay I, Fetics B, et al : Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations. Circulation 2003 107 : 714 720.
10. Eren M, Gorgulu S, Uslu N, et al : Relation between aortic stiffness and left ventricular diastolic function in patients with hypertension, diabetes, or both. Heart 2004 90 : 37 43.
11. Yambe M, Tomiyama H, Hirayama Y, et al : Arterial stiffening as a possible risk factor for both atherosclerosis and diastolic heart failure. Hypertens Res 2004 27 : 625 631.
12. Mizuguchi Y, Tanaka H, Oishi Y, et al : Predictive value of associations between carotid arterial sclerosis and left ventricular diastolic dysfunction in patients with cardiovascular risk factors. J Am Soc Echocardiogr 2007 20 : 806 812.
13. Benson SC, Pershadsingh HA, Ho CI, et al : Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004 43 : 993 1002.
14. Mattioli AV, Zennaro M, Bonatti S, et al : Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004 97 : 383 388.
15. Morimoto S, Yano Y, Maki K, et al : Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006 29 : 567 572.
16. Nakamura T, Inoue T, Suzuki T, et al : Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens Res 2008 31 : 841 850.
17. Lang RM, Bierig M, Devereux RB, et al : Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005 18 : 1440 1463.
18. Tei C : New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 1995 26 : 396 404.
19. Nagueh SF, Middleton KJ, Kopelen HA, et al : Doppler tissue imaging: A noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997 30 : 1527 1533.
20. Simons PCG, Algra A, Bots ML, et al : Common carotid intima-media thickness and arterial stiffness: Indicators of cardiovascular risk in high-risk patients. The SMART study (Second Manifestations of Arterial Disease). Circulation 1999 100 : 951 957.
21. Hirai T, Sasayama S, Kawasaki T, et al : Stiffness of systemic arteries in patients with myocardial infarction: A noninvasive method to predict severity of coronary atherosclerosis. Circulation 1989 80 : 78 86.
22. Dahlöf B, Devereux RB, Kjeldsen SE, et al : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002 359 : 995 1003. (Pubitemid 34286536)
23. Ricote M, Li AC, Willson TM, et al : The peroxisome proliferator- activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998 391 : 79 82.
24. Yamagishi S, Takeuchi M : Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 2005 64 : 476 478.
25. Benson SC, Iguchi R, Ho CI, et al : Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: Are all molecules the same J Hypertens 2008 26 : 973 980.
26. Lip GY : Regression of left ventricular hypertrophy and improved prognosis: Some HOPE now... or hype Circulation 2001 104 : 1582 1584.
27. Dahlöf B : Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 2001 14 : 174 182. (Pubitemid 32171571)
28. Klingbeil A, Schneider M, Martus P, et al : A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003 115 : 41 46.
29. Chrysant SG, Chrysant GS, Desai A : Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: Focus on telmisartan. J Hum Hypertens 2005 19 : 173 183.
30. Martina B, Dieterle T, Sigle JP, et al : Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial. Cardiology 2003 99 : 169 170.
31. Galzerano D, Tammaro P, del Viscovo L, et al : Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass. A multicenter, randomized, longitudinal study. Am J Hypertens 2005 18 : 1563 1569.
32. Oki T, Tabata T, Yamada H, et al : Left ventricular diastolic properties of hypertensive patients measured by pulsed tissue Doppler imaging. J Am Soc Echocardiogr 1998 11 : 1106 1112.
33. Mizuguchi Y, Oishi Y, Miyoshi H, et al : The functional role of longitudinal, circumferential, and radial myocardial deformation for regulating the early impairment of left ventricular contraction and relaxation in patients with cardiovascular risk factors: A study with two-dimensional strain imaging. J Am Soc Echocardiogr 2008 21 : 1138 1144.
34. Burlew BS, Weber KT : Cardiac fibrosis as a cause of cardiac dysfunction. Herz 2002 27 : 92 98.
35. Varo N, Iraburu MJ, Varela M, et al : Chronic AT1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000 35 : 1197 1202.
36. López B, Querejeta R, Varo N, et al : Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001 104 : 286 291.
37. Mandarim-de-Lacerda CA, Pereira LMM : Effect of telmisartan on preexistent cardiac and renal lesions in spontaneously hypertensive mature rats. Histol Histopathol 2004 19 : 727 733.
38. Onose Y, Oki T, Mishiro Y, et al : Influence of aging on systolic left ventricular wall motion velocities along the long and short axes in clinically normal patients determined by pulsed tissue Doppler imaging. J Am Soc Echocardiogr 1999 12 : 921 926. (Pubitemid 29533944)
39. Poulsen SH, Andersen NH, Ivarsen PI, et al : Doppler tissue imaging reveals systolic dysfunction in patients with hypertension and apparent "isolated" diastolic dysfunction. J Am Soc Echocardiogr 2003 16 : 724 731.
40. Bountioukos M, Schinkel AFL, Bax JJ, et al : The impact of hypertension on systolic and diastolic left ventricular function. A tissue Doppler echocardiographic study. Am Heart J 2006 151 : 1323 e5 e12.
41. Hsueh WA, Jackson S, Law RE : Control of vascular cell proliferation and migration by PPAR-gamma: A new approach to the macrovascular complications of diabetes. Diabetes Care 2001 24 : 392 397.
42. Schmieder RE, Fauvel JP, Delles C, et al : Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007 30 : 1351 1356.
43. Schupp M, Janke J, Clasen R, et al : Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004 109 : 2054 2057.
44. Sanchez RA, Masnatta LD, Pesiney C, et al : Telmisartan improves insulin resistance in high rennin nonmodulating salt-sensitive hypertensives. J Hypertens 2008 26 : 2393 2398.
45. Blacher J, Asmar R, Djane S, et al : Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999 33 : 1111 1117.
46. Oki T, Fukuda N, Iuchi A, et al : Effects of enalapril on left ventricular mass and diastolic function in essential hypertension: Special reference to duration of hypertension. J Card Fail 1995 1 : 365 370.
47. Protogerou A, Blacher J, Stergiou GS, et al : Blood pressure Response under chronic antihypertensive drug therapy. The role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study. J Am Coll Cardiol 2009 53 : 445 451.